The Company will use the net proceeds from the Offering to progress the Company's psychedelic therapies and nutraceutical products, as well as working capital and general corporate purposes. Updates Related to the Reverse-Takeover On August 13, 2020, Clarmin held an annual and special meeting of its shareholders (the " Shareholders "), pursuant to which the Shareholders approved the following matters relating to the Transaction: (i) the delisting of the common shares in the capital of Clarmin from the TSXV; (ii) the disposition of its mining assets; (iii) the new slate of directors to be appointed upon completion of the Transaction; and (iv) a name change to "Cybin Corporation", to be effective upon the completion of the Transaction. About CYBIN CYBIN is a life sciences company advancing psychedelic pharmaceutical therapies, delivery mechanisms, novel compounds and protocols as potential therapies for various psychiatric and neurological conditions.